Epkinly's first-line DLBCL win Read in browser

Thank you for reading, Test Researcher! basic Subscription UPGRADE

M Tue W Th F 6 October, 2026

Biopharma's balance of power is shifting, and in January, Endpoints journalists will press the people at the center of it on who's rising, who's falling and where the industry may land by the end of the decade. Join us at #JPM27 for exclusive conversations and interviews you won't get anywhere else. Save $200 on your all-access pass with Early Bird, or join us virtually for free.

presented by The Patent Clock Is Al­ready Run­ning. Why De­vel­op­ment Speed Is Al­so a Com­mer­cial Strat­e­gy

Spotlight Meet 20 women changing the biopharma industry, from oncology to rare disease

news Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy Exclusive: Genentech parts ways with a key AI leader in latest high-profile exit

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

ENDPOINTS PHARMA Leerink downgrades Bristol Myers, citing new skepticism of three advanced programs FDA delays Novo’s hemophilia A drug review over factory issues Exclusive: Startup gets $47M for mRNA therapy manufacturing platform Shionogi to pay $2B for IntraBio, a commercial rare disease biotech

in case you missed it 1. Nobel goes to scientists who paved the way for light-activated gene therapies 2.